Loading
A phase 1/2 trial of GFH375 in advanced solid tumours, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations is a phase 1/2 interventional study registered as NCT06500676 by Genfleet Therapeutics (Shanghai) Inc., with 407 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-07-31. Interventions recorded: GFH375.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GenFleet Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GFH375, GenFleet Therapeutics.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/